Glycaemic control in type 2 diabetic patients on chronic haemodialysis: Use of a continuous glucose monitoring system

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2866-2871

  Riveline, Jean Pierre ^a   Teynie, Julie ^b,c,d   Belmouaz, Simohamed ^b,c,d   Franc, Sylvia ^a   Dardari, Dured ^a   Bauwens, Marc ^b,c,d   Caudwell, Valérie ^a   Ragot, Stéphanie ^b   Bridoux, Frank ^b,c,d   Charpentier, Guillaume ^a   Marechaud, Richard ^b   Hadjadj, Samy ^b,c,d,e  

^a CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c Institut universitaire de santé publique Faculté de médecine pharmacie   (France)

^d UNIVERSITÉ DE POITIERS   (France)

^e INSERM   (France)

Author keywords

CGMS; Diabetes; Dialysis; End stage renal failure; Haemodialysis

Indexed keywords

FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS INTERSTITIAL GLUCOSE MONITORING SYSTEM; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 69249098196     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp181     Document Type: Article

References (38)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. U.S. Renal Data System. USRDS 2007 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007
3. Kimmel PL, Varela MP, Peterson RA et al. Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. Kidney Int 2000; 57: 1141-1151
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389
5. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
6. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
7. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720
8. Khaw K-T, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer andNutrition (EPIC-Norfolk). BMJ 2001; 332: 996-999
9. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
10. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1c and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055
11. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913
12. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500
13. Williams ME, Lacson E Jr, Teng M et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-1509
14. McCance DR, Clarke KC, Kennedy L. Serum fructosamine in uraemia, myeloma and acute inflammatory disorders-relationship to serum glucose and albumin levels. Ann Clin Biochem 1989; 26(Pt 1): 63-68
15. Morgan L, Marenah CB, Jeffcoate WJ et al. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 1996; 13: 514-519
16. Boland E, Monsod T, Delucia M et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001; 24: 1858-1862
17. Kaufman FR, Austin J, Neinstein A et al. Nocturnal hypoglycemia detected with the continuous glucose monitoring system in pediatric patients with type 1 diabetes. J Pediatr 2002; 141: 625-630
18. Kaufman FR, Gibson LC, HalvorsonMet al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001; 24: 2030-2034
19. Lu H, Castells S, Hagerty D et al. Study of glucose profiles with continuous glucose monitoring in adolescents with poorly controlled type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2008; 21: 729-736
20. Ludvigsson J, Hanas R. Continuous subcutaneous glucosemonitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003; 111: 933-938
21. Murphy HR, Rayman G, Lewis K et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008; 337: a1680
22. Deiss D, Bolinder J, Riveline JP et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730-2732
23. Tamborlane WV, Beck RW, Bode BW et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476
24. Tubiana-Rufi N, Riveline JP, Dardari D. Real-time continuous glucose monitoring using GuardianRT: from research to clinical practice. Diabetes Metab 2007; 33: 415-420
25. Bland J, Altman D. Statistical methods for assessing agreement between twomethods of clinical measurement. Lancet 1986; 1: 307-310
26. Chico A, Vidal-Rios P, Subira M et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003; 26: 1153-1157
27. Dandona P, Freedman D,Moorhead JF. Glycosylated haemoglobin in chronic renal failure. Br Med J 1979; 1: 1183-1184
28. de Boer MJ, Miedema K, Casparie AF. Glycosylated haemoglobin in renal failure. Diabetologia 1980; 18: 437-440
29. Joy MS, Cefalu WT, Hogan SL et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307
30. Zoungas S, Kerr PG, Lui M et al. The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes. Nephrology (Carlton, Vic) 2008; 13: 124-127
31. Chujo K, Shima K, Tada H et al. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 2006; 53: 223-228
32. Okada T, Nakao T, Matsumoto H et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med (Tokyo, Japan) 2007; 46: 807-814
33. Peacock TP, Shihabi ZK, Bleyer AJ et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062-1068
34. Pitkanen E, Koivula T. Continuous blood glucose monitoring and characteristics of diabetes in patients on maintenance haemodialysis treatment. Scand J Urol Nephrol 1979; 13: 309-312
35. Abe M, Kaizu K, Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther Apher Dial 2007; 11: 280-287
36. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64: 1480-1486
37. Tascona DJ, Morton AR, Toffelmire EB et al. Adequacy of glycemic control in hemodialysis patients with diabetes. Diabetes Care 2006; 29: 2247-2251
38. Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabet Technol Ther 2000; 2: 461-472